secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001104659-23-092219
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia acquires exclusive U.S. rights to Formosa's APP13007 (clobetasol) for ocular surgery inflammation/pain
--------------------------------------------------------------------------------

- PDUFA action date for APP13007 (clobetasol) set for March 4, 2024.
- Upfront payment of single-digit million in cash and stock; up to $4M in development and $80M in sales milestones.
- APP13007 offers 2x/day dosing vs. standard 4x/day for post-surgical ocular inflammation/pain.
- Eyenovia plans to develop clobetasol-Optejet for dry eye, a $3.6B U.S. market.
- Product complements existing Mydcombi sales force; addresses >7M annual ocular surgeries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465923092219/0001104659-23-092219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465923092219/tm2323901d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-092219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer